As reported (here) previously, the stem cell treatment for ALS from Israel’s Brainstorm is doing well in trials.  The latest Phase 2 trial of Brainstorm’s autologous bone-marrow derived MSC-NTF cells (Nurown) in 48 patients at 3 US sites was effective … Continue reading →

New ABC TV video of the 4-year human trials of the stem cell treatment from Israel’s Brainstorm on 26 ALS patients at Jerusalem’s Hadassah Medical Center. 90% have shown positive change. The patients’ own bone marrow stem cells are extracted, … Continue reading →

A four-year study at Jerusalem’s Hadassah hospital of the stem cell treatment from Israel’s Brainstorm has been shown to inhibit the progression of the fatal neurological disease ALS (Lou Gehrig’s) in 87 percent of 26 patients. http://www.jpost.com/Business-and-Innovation/Health-and-Science/Optimistic-results-for-Phase-ALS-treatment-at-Jerusalem-hospital-441407

Israel’s Brainstorm has announced positive final results from its phase 2a clinical trial of NurOwn cells in amyotrophic lateral sclerosis (ALS) patients used on 14 subjects at Hadassah Medical Center in Jerusalem.  Nearly all subjects experienced clinical benefit. http://www.brainstorm-cell.com/index.php/news-events/331-january-5-2015

The US FDA has designated NurOwn, developed by Israel’s Brainstorm, as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s Disease). http://jewishbusinessnews.com/2014/10/08/brainstorms-stem-cell-based-drug-nurown-gets-fda-fast-track-approval/

Israel’s BrainStorm reported positive interim results of Phase IIa ALS trials of its “NurOwn” stem cell therapy. 71% of patients were in decline before treatment but after treatment 63% were either stabilized or had improved neurological function. http://www.brainstorm-cell.com/index.php/news-a-events/302-june-2-2014

Professor Dimitrios Karussis, Principal Investigator of BrainStorm’s clinical trials of its ALS stem cell treatment at Jerusalem’s Hadassah Medical Center, will present at the Joint Congress of European Neurology, May 31-June 3 in Istanbul, Turkey. http://www.brainstorm-cell.com/index.php/news-a-events/299-may-19-2014

(Thanks to NoCamels) ALS (Lou Gehrig’s) sufferer Rabbi Refael Shmulevitz had been given two to four years to live. He lost the ability to talk clearly and was confined to a wheelchair. Following Brainstorm‘s ‘NurOwn’ stem cell treatment he can … Continue reading →

Israel’s BrainStorm (reported here previously) reported promising results of pre-clinical trials for its Nurown treatment for Acute Respiratory Distress Syndrome (ARDS) brought about by Covid-19. The NurOwn cells reduced the cytokine storm and lung damage. https://ir.brainstorm-cell.com/2020-07-23-BrainStorm-Announces-Groundbreaking-Pre-Clinical-Study-of-NurOwn-R-derived-Exosome-Based-Treatment-for-COVID-19-ARDS